Gilead: HIV growth and Yeztugo momentum support a broader pipeline

Transcript intelligence

What changed

Relative to the prior-quarter analysis, the current analysis adds 75% Yeztugo payer coverage, more explicit 2026 launch and regulatory milestones, and a quantified Medicare Part D headwind. The underlying narrative remains constructive, but uptake, formulary and execution risks remain central.

Guidance delta

Management raised full-year HIV revenue growth guidance to approximately 5%, despite a stated $900 million Medicare Part D redesign headwind.

Key takeaways

• Yeztugo reached 75% payer coverage three months ahead of schedule, supporting the company’s stated 2026 growth outlook.
• HIV franchise momentum remained the central growth driver, while Livdelzi surpassed $100 million in quarterly sales.
• Pipeline milestones in bulevirtide, Trodelvy and ARTISTRY add potential catalysts, but depend on regulatory and launch execution.
• The quarter extended the prior period’s constructive setup: strong Yeztugo rollout and raised HIV expectations, with policy and uptake risks still present.

Management priorities

• Expand Yeztugo payer coverage and manage launch inventory.
• Advance ARTISTRY and cell-therapy programs.
• Pursue regulatory and commercial progress for bulevirtide and first-line Trodelvy.
• Maintain expense discipline while investing in the pipeline.